BROADCASTS.com

b'

Andrew\\xa0Bascand,\\xa0Managing Director of Harbour Asset Management joins me to discuss new findings of the\\xa0GLP-1 drug class, which has\\xa0predominantly been used to treat type 2 diabetes but has captured notable mindshare with healthcare specialists and macro investors.

Listen in for your chance to get ahead of the markets.

LISTEN ABOVE

See omnystudio.com/listener for privacy information.